RxDoctor Payments Data

Patricia Stringer, MD

Internal Medicine · Arlington Heights, ILNPI 1033115423

Payments from drug & device makers

$15,690in general payments, 2019–2025

Across 869 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$2K
  • Boehringer Ingelheim$2K
  • Lilly USA, LLC$1K
  • Amgen$1K
  • GSK$1K
  • plus $7K from 42 others

What the payments were for

  • Food & beverage$15,57199%
  • Education$1191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,690 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$317,874
Medicare patients
914
Services billed
4,757

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban799$451,871
OzempicSemaglutide79$116,951
XareltoRivaroxaban143$86,282
JardianceEmpagliflozin146$77,195
TrulicityDulaglutide37$64,749
MyrbetriqMirabegron75$52,412
GemtesaVibegron78$46,612
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$41,156
FarxigaDapagliflozin Propanediol37$37,844
ProliaDenosumab18$31,553
MounjaroTirzepatide22$29,588
Breo ElliptaFluticasone/Vilanterol49$22,377
LinzessLinaclotide24$16,982
Bumetanide405$16,727
InpefaSotagliflozin15$16,106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$950$451,871799 claims
Novo NordiskOzempic$1,039$116,95179 claims
Lilly USA, LLCTrulicity, Mounjaro$1,286$94,33759 claims
Johnson & JohnsonXarelto$499$86,282143 claims
Boehringer IngelheimJardiance$1,520$77,195146 claims
GSKTrelegy Ellipta, Breo Ellipta$1,052$63,53390 claims
Astellas Pharma US IncMyrbetriq$333$52,41275 claims
Sumitomo Pharma America, Inc.Gemtesa$216$46,61278 claims
AstraZenecaFarxiga$1,800$37,84437 claims
AmgenProlia$1,188$31,55318 claims
AbbVieLinzess, Synthroid$1,540$22,437136 claims
Lexicon Pharmaceuticals, Inc.Inpefa$221$16,10615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Arlington Heights

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →